Dommergues M-A
Centre Hospitalier de Versailles, 177, rue de Versailles, 78150 Le Chesnay, France.
Arch Pediatr. 2012 Sep;19 Suppl 2:S65-9. doi: 10.1016/S0929-693X(12)71276-9.
The diversity and antigenic variability of Neisseria meningitidis serogroup B strains around the world has been a major challenge to developing a vaccine with broad coverage. Outer-membrane vesicle vaccines appear to be safe and effective but are strain-specific vaccines and used in delimited areas. Also, recombinant protein vaccines such as factor H binding protein, given alone or in combination with others antigens have been developed and may be effective against the majority of group B strains.
全球范围内B群脑膜炎奈瑟菌菌株的多样性和抗原变异性一直是开发具有广泛覆盖范围疫苗的主要挑战。外膜囊泡疫苗似乎安全有效，但属于菌株特异性疫苗，仅在特定区域使用。此外，已经开发出单独使用或与其他抗原联合使用的重组蛋白疫苗，如因子H结合蛋白，可能对大多数B群菌株有效。
